Difference between revisions of "Oxaliplatin (Eloxatin)"

Revision as of 13:26, 10 December 2021

General information

Class/mechanism: Platinum analog, alkylating-like, which produces interstrand and intrastrand DNA crosslinks that inhibit DNA replication and transcription, causing non-cell cycle specific cytotoxicity and death.^[1]^[2]^[3]
Route: IV
Extravasation: irritant (usually), vesicant (rare)

Oxaliplatin desensitization protocol

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

8/9/2002: Initial accelerated approval in combination with infusional 5-FU/ LV, is indicated for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/ LV and irinotecan.
1/9/2004: Converted to regular approval in combination with infusional 5-FU/ LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.
11/4/2004: New indication: "used in combination with infusional 5-FU/ LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.

Also known as

Code names: JM-83, RP-54780, SR-96669
Brand names: Coxatin, Curaplat, Cure-X, Dacotin, Dacplat, Eloplat, Eloxatin, Eloxatine, Oplatin, OxaLitin, Oxiplat, Oxitan, Oxzucia, Sibatin, Xaloplat, Xylotin, X-Plat, Zildox

References

[insert-1] 1.0 ^1.1 ^1.2 Oxaliplatin (Eloxatin) package insert

[2] Oxaliplatin (Eloxatin) package insert (locally hosted backup)

[3] Eloxatin manufacturer's website

[4] Oxaliplatin (Eloxatin) patient drug information (Chemocare)

[5] Oxaliplatin (Eloxatin) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]

@@ Line 30: / Line 30: @@
 ==History of changes in FDA indication==
-* 8/9/2002: Initial FDA approval: "used in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for the treatment of patients with metastatic carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]] whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]] and [[Irinotecan (Camptosar) | irinotecan]]."
+* 8/9/2002: Initial accelerated approval in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for the treatment of patients with metastatic carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]] whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]] and [[Irinotecan (Camptosar) | irinotecan]].
-* 1/9/2004: Indication revised: "used in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for the treatment of advanced carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]].
+* 1/9/2004: Converted to regular approval in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for the treatment of advanced carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]].
 * 11/4/2004: New indication: "used in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for adjuvant treatment of stage III [[Colon cancer | colon cancer]] patients who have undergone complete resection of the primary tumor.